Adjunctive cenobamate in highly active and ultra‐refractory focal epilepsy: A “real‐world” retrospective study

Abstract

Patients with highly active and ultra-refractory focal epilepsy experienced meaningful seizure outcomes on cenobamate. Emergence of adverse events at doses above 250 mg/day may limit the potential for further improvements in seizure control at higher cenobamate doses.